Early report on modular BioVAT patches in advanced stage C or D disease ...

Germany: Interim findings from an early-stage study suggest that BioVAT, a tissue-engineered cardiac muscle patch therapy, may help remuscularize the heart in patients with advanced heart ...

Researchers at the University Medical Center Göttingen (UMG) and the University Hospital of Schleswig-Holstein (UKSH) have made a significant breakthrough in the treatment of severe heart failure: For ...

Cardiac gene therapy was once viewed as a promising breakthrough before high-profile clinical setbacks dampened expectations. Now, advances in gene delivery, viral vectors and molecular targeting are ...

Repairon, a biotechnology company developing regenerative cardiac therapies, today announced that clinical results evaluating its engineered human heart muscle tissue for patients with advanced heart ...

Using patient-derived cardiac tissue and stem cell-based models, the team of translational researchers demonstrated that targeting the genetic cause of disease improved cellular abnormalities and ...

Researchers have developed a scalable bioreactor-based system to produce cardiac organoids that successfully integrated into ...

Using patient-derived cardiac tissue and stem cell-based models, the team of translational researchers demonstrated that targeting the genetic cause of disease improved cellular abnormalities and ...

Secretome raises $30M Series A to advance STM-01 into Phase 2 and 3 late-stage trials for Duchenne cardiomyopathy treatment.

While interventional cardiology wasn’t directly aligned with drug discovery, interacting with patients every week and seeing their journeys and problems was instructive. For instance, you see that ...

The next time you train, remember: You’re not just building endurance. You’re upgrading your heart's software. You're ...

Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soonHOPE-3 Phase 3 ...